Cyclerion Therapeutics, Inc.·4/A

Jul 27, 4:40 PM ET

Hyman Steven 4/A

4/A · Cyclerion Therapeutics, Inc. · Filed Jul 27, 2022

Insider Transaction Report

Form 4/AAmended
Period: 2022-07-25
Hyman Steven
Director
Transactions
  • Award

    Stock Option (Right to Buy)

    2022-07-25+57,75357,753 total
    Exercise: $0.78Exp: 2032-07-25Common Stock (57,753 underlying)
Footnotes (1)
  • [F1]The options were granted pursuant to the director compensation plan. 17,753 options will vest in full on the first anniversary of the grant date and 40,000 options will vest monthly pro rata over 36 months starting on the grant date.

Documents

1 file
  • 4
    form4.xml

    FORM 4/A